(Q28165227)

1

0 references

E Lindenstrom

2

0 references

G Boysen

3

0 references

P De Deyn

4

0 references

P Friis

5

0 references

D Leys

6

0 references

R Marttila

7

0 references

J Olsson

8

0 references

D O'Neill

9

0 references

J Orgogozo

10

0 references

B Ringelstein

11

0 references

J van der Sande

12

0 references

A G Turpie

Antithrombotic therapy for cerebrovascular disorders. An update

13

0 references

language of work or name

English

0 references

publication date

1 September 2001

0 references

published in

The Lancet

0 references

volume

358

0 references

issue

9283

0 references

page(s)

702-10

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Antithrombotic and thrombolytic therapy for ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Low molecular weight heparin in prevention of perioperative thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Low molecular weight heparin in acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Low-molecular-weight heparins and heparinoids in acute ischemic stroke : a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Use of the Barthel index and modified Rankin scale in acute stroke trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Classification and natural history of clinically identifiable subtypes of cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Acute Treatment of Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021

Heparin in acute ischemic stroke: the case for a new clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2905837-8

7 January 2021